Key result
Loss of cardiac micropeptide IAMP exacerbates ischemia/reperfusion injury by promoting HIF-1α-mediated inflammation.
Why the study?
Immunosuppressive therapies improve outcomes in myocardial infarction but increase infection risk, necessitating novel regulators of local cardiac inflammation as safer therapeutic targets.
Does modulation of IAMP regulate inflammation and cardiac injury in myocardial ischemia/reperfusion models?
Does modulation of IAMP regulate inflammation and cardiac injury in myocardial ischemia/reperfusion models?
The discovery of IAMP highlights a novel mechanism regulating fibroblast-mediated inflammation via HIF-1α degradation, offering a potential therapeutic target for myocardial ischemia/reperfusion injury.
Answers are grounded in this paper and cite their sources.
IAMP may be a target to limit inflammation in ischemia/reperfusion injury; hypothesis-generating in animal models, requiring human validation.
Inflammation is a critical pathological process in myocardial infarction. Although immunosuppressive therapies can mitigate inflammatory responses and improve outcomes in myocardial infarction, they also increase the risk of infections. Identifying novel regulators of local cardiac inflammation could provide safer therapeutic targets for myocardial ischemia/reperfusion injury. In this study, we identified a previously uncharacterized micropeptide, which we named Inflammation Associated MicroPeptide (IAMP). IAMP is predominantly expressed in cardiac fibroblasts, and its expression is closely associated with cardiac inflammation. Downregulation of IAMP promotes, whereas its overexpression prevents, the transformation of cardiac fibroblasts into a more inflammatory phenotype under stressed/stimulated conditions, as evidenced by changes in the expression and secretion of proinflammatory cytokines. Consequently, loss of IAMP function leads to uncontrolled inflammation and worsens cardiac injury following ischemia/reperfusion surgery. Mechanistically, IAMP promotes the degradation of HIF-1α by interacting with its stabilizing partner HSP90 and, thus, suppresses the transcription of proinflammatory genes downstream of HIF-1α. This study underscores the significance of fibroblast-mediated inflammation in cardiac ischemia/reperfusion injury and highlights the therapeutic potential of targeting micropeptides for myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2025) studied Myocardial ischemia/reperfusion injury. IAMP knockout/knockdown vs. Wild-type/Control was evaluated on Infarct size and cardiac inflammation. Loss of the cardiac fibroblast-enriched micropeptide IAMP exacerbates myocardial ischemia/reperfusion injury by promoting HIF-1α-mediated inflammation.
Synapse has enriched 10 related papers. Consider them for comparative context: